Cu-7

(Copper)

Phase 2Small molecule

CCoopersurgical

Cu-7 is one of 88 small molecule programs targeting Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Prostate CancerActive, not recruiting

GlioblastomaActive, not recruiting

Breast CancerPhase 2

Active, not recruiting

Prostate CancerPhase 1

Active, not recruiting

GlioblastomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Avastin

BBio-Thera Solutions

Preclinical

153 3

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 4

Cu-7

CCoopersurgical

Phase 2

1 5

Prolia

Amgen

Preclinical

14 6

MS Contin

Merck & Co.

Preclinical

2 7

Voltaren

Novartis

Preclinical

1 8

Zolymbus

AbbVie

Preclinical

1 9

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 10

Tricor

JJagotec

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

Phase 2Not yet recruiting

Glioblastoma

NCT01777919

Clinical

Trials by Indication[1]

Prostate Cancer1 trial

A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer

Terminated·—·Phase 1·NCT02963051·9 enrolled

Glioblastoma1 trial

Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform

Not yet recruiting·OOlympion Medical Center·Phase 2·NCT01777919·32 enrolled

Breast Cancer1 trial

Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.

Withdrawn·NNational Cancer Institute, Slovakia·Phase 2·NCT04265274

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

CU-7

NDA NDA017408

Jan 1, 1982

TATUM-T

NDA NDA018205

Nov 15, 1984

PARAGARD T 380A

NDA NDA018680

Feb 24, 2025

MIUDELLA

NDA NDA218201

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Copper. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Copper compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Copper. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA218201). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Cu-7. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Coopersurgical company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCoopersurgical

Patent Landscape[5]

Patent Cliff

Aug 14, 2032

Earliest patent expiration — generic entry possible after this date

Patent #Expires

10159596Aug 14, 2032

9427351Aug 14, 2032

11850181Aug 14, 2032

10188546Aug 14, 2032

9089418Apr 9, 2033

9 more patents

12138199Oct 18, 2033

9610191Feb 24, 2034

10398588Feb 24, 2034

9180040Mar 22, 2034

10022264Mar 22, 2034

9265652Apr 28, 2034

10166141Jun 13, 2034

11207209Aug 16, 2034

10918516Jan 23, 2037

Cu-7

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

Prostate Cancer1 trial

Glioblastoma1 trial

Breast Cancer1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News